Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (26)
Robert A Sandhaus, Charlie Strange, Andrea Zanichelli, Karen Skålvoll, Andreas Rembert Koczulla & Robert A Stockley. (2020) Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3313-3322.
Read now
Read now
Tanja Plate, Felix W Friedrich & Jutta Beier. (2020) Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1335-1347.
Read now
Read now
Konstantinos Kostikas, Theodoros I Vassilakopoulos, Nikos Tzanakis, Athanasios K Konstantinidis, Epameinondas N Kosmas, Spyros Papiris, Paschalis Steiropoulos, Effrosyni D Manali, Stylianos A Michaelides & Grigorios Daskos. (2020) A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 515-526.
Read now
Read now
Sanjay Sethi, Edward Kerwin, Henrik Watz, Gary T Ferguson, Robert M Mroz, Rosa Segarra, Eduard Molins, Diana Jarreta & Esther Garcia Gil. (2019) AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 667-682.
Read now
Read now
Helgo Magnussen, Beatrix Fyrnys & Roland Greguletz. (2019) Genuair®/Pressair® Inhaler in COPD: The Patient Perspective. COPD: Journal of Chronic Obstructive Pulmonary Disease 16:2, pages 196-205.
Read now
Read now
Edward Kerwin & Gary T. Ferguson. (2018) An overview of glycopyrrolate/eFlow® CS in COPD. Expert Review of Respiratory Medicine 12:6, pages 447-459.
Read now
Read now
Mario Malerba, Alessandro Radaeli, Giuseppe Santini, Jaymin Morjaria, Nadia Mores, Chiara Mondino, Giuseppe Macis & Paolo Montuschi. (2018) The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery 13:6, pages 563-577.
Read now
Read now
Jutta Beier, Robert Mroz, Anne-Marie Kirsten, Ferran Chuecos & Esther Garcia Gil. (2017) Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1731-1740.
Read now
Read now
Klaus F. Rabe. (2017) GFF MDI for the improvement of lung function in COPD – A look at the PINNACLE-1 and PINNACLE-2 data and beyond. Expert Review of Clinical Pharmacology 10:7, pages 685-698.
Read now
Read now
Amanda R. van Buul, Marise J. Kasteleyn, Niels H. Chavannes & Christian Taube. (2017) Morning symptoms in COPD: a treatable yet often overlooked factor. Expert Review of Respiratory Medicine 11:4, pages 311-322.
Read now
Read now
Antonio Anzueto & Marc Miravitlles. (2017) Pathophysiology of dyspnea in COPD. Postgraduate Medicine 129:3, pages 366-374.
Read now
Read now
Maria Gabriella Matera, Alessandro Sanduzzi, Roberto Alfano & Mario Cazzola. (2016) Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. Expert Review of Clinical Pharmacology 9:6, pages 771-777.
Read now
Read now
Marco Contoli, Paolo Solidoro, Fabiano Di Marco, Nicola Scichilone, Angelo Corsico, Fulvio Braido & Pierachille Santus. (2016) Effects of aclidinium on determinants of COPD severity: symptoms and quality of life. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 3043-3050.
Read now
Read now
Gregory Feldman, François Maltais, Sanjeev Khindri, Mitra Vahdati-Bolouri, Alison Church, William A Fahy & Roopa Trivedi. (2016) A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 719-730.
Read now
Read now
Jose Luis Lopez-Campos, Carmen Calero, Cecilia Lopez-Ramirez, Maria Isabel Asensio-Cruz, Eduardo Márquez-Martín & Francisco Ortega-Ruiz. (2015) Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Preference and Adherence 9, pages 95-104.
Read now
Read now
Subhabrata Moitra, Arvind B Bhome & Bill B Brashier. (2015) Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Design, Development and Therapy 9, pages 1989-1999.
Read now
Read now
Saiprasad Narsingam, Andrew L. Bozarth & Asem Abdeljalil. (2015) Updates in the management of stable chronic obstructive pulmonary disease. Postgraduate Medicine 127:7, pages 758-770.
Read now
Read now
Andrea S Melani. (2015) Long-acting muscarinic antagonists. Expert Review of Clinical Pharmacology 8:4, pages 479-501.
Read now
Read now
Afisi Segun Ismaila, Eline L Huisman, Yogesh Suresh Punekar & Andreas Karabis. (2015) Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 2495-2517.
Read now
Read now
Basil G Bereza, Anders Troelsgaard Nielsen, Sverrir Valgardsson, Michiel EH Hemels & Thomas R Einarson. (2015) Patient preferences in severe COPD and asthma: a comprehensive literature review. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 739-744.
Read now
Read now
Andrea Zanini, Francesca Cherubino, Elisabetta Zampogna, Stefania Croce, Patrizia Pignatti & Antonio Spanevello. (2015) Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1155-1161.
Read now
Read now
Paul W Jones. (2015) Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 677-687.
Read now
Read now
Jun Zhong & Michael Roth. (2014) Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Therapeutics and Clinical Risk Management 10, pages 449-453.
Read now
Read now
Debra J Reid & Alexa A Carlson. (2014) Clinical use of aclidinium in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 369-379.
Read now
Read now
Emily M. Armstrong, Bradley M. Wright, Allison Meyer, Courtney S. Watts & Kristi W. Kelley. (2014) The Role of Aclidinium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease. Hospital Practice 42:4, pages 99-110.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2014) Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 15:7, pages 961-977.
Read now
Read now
Articles from other publishers (57)
O. N. Titova, N. A. Kuzubova & A. G. Kozyrev. (2023) Tiotropium bromide in the treatment of chronic obstructive pulmonary disease. PULMONOLOGIYA 33:6, pages 810-818.
Crossref
Crossref
Maria Gabriella Matera, Barbara Rinaldi, Concetta Ambrosio & Mario Cazzola. (2023) Is it preferable to administer a bronchodilator once- or twice-daily when treating COPD?. Respiratory Medicine 219, pages 107439.
Crossref
Crossref
O. N. Titova, N. A. Kuzubova, A. G. Kozyrev & A. A. Shumilov. (2023) Bronchodilator therapy in patients with chronic obstructive pulmonary disease: what should be considered in clinical practice when choosing a dosing regimen?. PULMONOLOGIYA 33:1, pages 44-50.
Crossref
Crossref
Luigino Calzetta, Beatrice Ludovica Ritondo, Maria Cristina Zappa, Gian Marco Manzetti, Andrea Perduno, Janis Shute & Paola Rogliani. (2022) The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. European Respiratory Review 31:164, pages 210196.
Crossref
Crossref
Fulvio Braido, Angelo G. Corsico, Davide Paleari, Alessio Piraino, Luca Cavalieri & Nicola Scichilone. (2022) Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution. Therapeutic Advances in Respiratory Disease 16, pages 175346662110660.
Crossref
Crossref
Mazen Tolaymat, Margaret H. Sundel, Madeline Alizadeh, Guofeng Xie & Jean-Pierre Raufman. (2021) Potential Role for Combined Subtype-Selective Targeting of M1 and M3 Muscarinic Receptors in Gastrointestinal and Liver Diseases. Frontiers in Pharmacology 12.
Crossref
Crossref
Antonio Anzueto & Marc Miravitlles. (2020) Tiotropium in chronic obstructive pulmonary disease – a review of clinical development. Respiratory Research 21:1.
Crossref
Crossref
Ioanna Tsiligianni & Janwillem W. H. Kocks. (2020) Daytime symptoms of chronic obstructive pulmonary disease: a systematic review. npj Primary Care Respiratory Medicine 30:1.
Crossref
Crossref
Helen Boreham. (2019) Living with Alpha-1 Antitrypsin Deficiency: Empowering Patients and Healthcare Professionals. EMJ Respiratory, pages 51-58.
Crossref
Crossref
Tadashi Kamei, Hiroyuki NakamuraDr.Dr., Nobuki NankiDr.Dr., Yoshiaki MinakataDr.Dr., Kazuto MatsunagaDr.Dr. & Yoshihiro MoriDr.Dr.. (2019) Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study. BMJ Open 9:7, pages e024114.
Crossref
Crossref
A. A. Vizel & I. Yu. Vizel. (2018) 12-Hour fixed-dose combination of andrenergic agonist and cholinergic antagonist in a new administration device: analytical review. Medical Council:15, pages 116-122.
Crossref
Crossref
Peter Strong, Kazuhiro Ito, John Murray & Garth Rapeport. (2018) Current approaches to the discovery of novel inhaled medicines. Drug Discovery Today 23:10, pages 1705-1717.
Crossref
Crossref
Emmanuel Naline, Stanislas Grassin Delyle, Hélène Salvator, Marion Brollo, Christophe Faisy, Tatiana Victoni, Charlotte Abrial & Philippe Devillier. (2018) Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulmonary Pharmacology & Therapeutics 49, pages 46-53.
Crossref
Crossref
Yong-Bum Park, Chin Kook RheeHyoung Kyu YoonYeon-Mok OhSeong Yong LimJin Hwa LeeKwang-Ha Yoo & Joong Hyun Ahn. (2018) Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary. Tuberculosis and Respiratory Diseases 81:4, pages 261.
Crossref
Crossref
Lindsay G.S. Bengtson, Michael DePietro, Jeffrey McPheeters & Kathleen M. Fox. (2018) Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy. Therapeutic Advances in Respiratory Disease 12, pages 175346661877275.
Crossref
Crossref
Colin Reisner, Gregory Gottschlich, Faisal Fakih, Andras Koser, James Krainson, Luis Delacruz, Samir Arora, Gregory Feldman, Krishna Pudi, Shahid Siddiqui, Chad Orevillo, Andrea Maes, Earl St. Rose & Ubaldo Martin. (2017) 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. Respiratory Research 18:1.
Crossref
Crossref
F. Blasi, G. W. Canonica & M. Miravitlles. (2017) Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?. Respiratory Research 18:1.
Crossref
Crossref
Colin Reisner, Leonardo M. Fabbri, Edward M. Kerwin, Charles Fogarty, Selwyn Spangenthal, Klaus F. Rabe, Gary T. Ferguson, Fernando J. Martinez, James F. Donohue, Patrick Darken, Earl St. Rose, Chad Orevillo, Shannon Strom, Tracy Fischer, Michael Golden & Sarvajna Dwivedi. (2017) A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respiratory Research 18:1.
Crossref
Crossref
David M. Halpin, Alan G. Kaplan & Richard K. Russell. (2017) Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respiratory Medicine 128, pages 28-41.
Crossref
Crossref
Hiroyuki Ohbayashi, Sahori Kudo & Masatake Ishikawa. (2017) Inhaler Operability and Patient Satisfaction Regarding Genuair® and Respimat® Inhalers for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Study. Pulmonary Therapy 3:1, pages 173-185.
Crossref
Crossref
Fabiano Di Marco, Pierachille Santus, Nicola Scichilone, Paolo Solidoro, Marco Contoli, Fulvio Braido & Angelo Guido Corsico. (2017) Symptom variability and control in COPD: Advantages of dual bronchodilation therapy. Respiratory Medicine 125, pages 49-56.
Crossref
Crossref
Swati Gulati & J. Michael Wells. (2017) Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators. Drugs 77:6, pages 651-670.
Crossref
Crossref
L. A. Shpagina, I. S. Shpagin, O. S. Kotova, T. I. Pospelova & O. N. Gerasimenko. (2017) Treatment of different phenotypes of chronic obstructive pulmonary disease. PULMONOLOGIYA 26:6, pages 681-693.
Crossref
Crossref
Hyoung Kyu YoonYong-Bum ParkChin Kook RheeJin Hwa LeeYeon-Mok Oh. (2017) Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease. Tuberculosis and Respiratory Diseases 80:3, pages 230.
Crossref
Crossref
Kevin Marsh, Erica Zaiser, Panagiotis Orfanos, Suzanne Salverda, Teresa Wilcox, Shawn Sun & Shailja Dixit. (2017) Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States. Value in Health 20:1, pages 132-140.
Crossref
Crossref
Roberto W. Dal Negro & Massimiliano Povero. (2016) Dry-powder inhalers in patients with persistent airflow limitation: usability and preference. Multidisciplinary Respiratory Medicine 11:1.
Crossref
Crossref
Leonardo M. Fabbri, Edward M. Kerwin, Selwyn Spangenthal, Gary T. Ferguson, Roberto Rodriguez-Roisin, James Pearle, Sanjay Sethi, Chad Orevillo, Patrick Darken, Earl St. Rose, Tracy Fischer, Michael Golden, Sarvajna Dwivedi & Colin Reisner. (2016) Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Respiratory Research 17:1.
Crossref
Crossref
Peter M. A. Calverley, Stephen I. Rennard, Emmanuelle Clerisme-Beaty, Norbert Metzdorf, Valentina Bayer Zubek & Richard ZuWallack. (2016) Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD. Respiratory Research 17:1.
Crossref
Crossref
M. Zysman, F. Chabot, P. Devillier, B. Housset, C. Morelot-Panzini & N. Roche. (2016) Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Société de Pneumologie de Langue Française. Revue des Maladies Respiratoires 33:10, pages 911-936.
Crossref
Crossref
Paolo Montuschi, Mario Malerba, Giuseppe Macis, Nadia Mores & Giuseppe Santini. (2016) Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discovery Today 21:11, pages 1820-1827.
Crossref
Crossref
G.P. Currie & B.J. Lipworth. (2016) Inhaled treatment for chronic obstructive pulmonary disease: what’s new and how does it fit?. QJM 109:8, pages 505-512.
Crossref
Crossref
Donatella Mutolo, Elenia Cinelli, Ludovica Iovino, Tito Pantaleo & Fulvia Bongianni. (2016) Downregulation of the cough reflex by aclidinium and tiotropium in awake and anesthetized rabbits. Pulmonary Pharmacology & Therapeutics 38, pages 1-9.
Crossref
Crossref
Monika Laššánová, Štefan Laššán, Jana Tisoňová & Peter Krištúfek. (2016) Abstract. Klinická farmakologie a farmacie 30:1, pages 16-21.
Crossref
Crossref
Arvind Manoharan, Ashley E. Morrison & Brian J. Lipworth. (2016) Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD. Lung 194:2, pages 259-266.
Crossref
Crossref
F. Т. Malykhin & V. A. Baturin. (2016) Possible side effects of drugs in elderly patients with chronic obstructive pulmonary disease and comorbidity. Terapevticheskii arkhiv 88:3, pages 100.
Crossref
Crossref
Eric D. Bateman, Kenneth R. Chapman, Dave Singh, Anthony D. D’Urzo, Eduard Molins, Anne Leselbaum & Esther Garcia Gil. (2015) Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research 16:1.
Crossref
Crossref
Christopher Lambers, Luigi Costa, Qi Ying, Jun Zhong, Didier Lardinois, Gerhard Dekan, Elisabeth Schuller & Michael Roth. (2015) Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP. Pharmacological Research 102, pages 310-318.
Crossref
Crossref
Christine Vetter. (2015) Mit zwei Hebeln die COPD im Griff. Pneumo News 7:5, pages 68-68.
Crossref
Crossref
Jutta Beier. (2015) A twice-daily, fixed-dose combination of aclidinium bromide and formoterol fumarate for the treatment of chronic obstructive pulmonary disease. Clinical Investigation 5:8, pages 691-700.
Crossref
Crossref
Paolo Montuschi & Giovanni Ciabattoni. (2015) Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends. Journal of Medicinal Chemistry 58:10, pages 4131-4164.
Crossref
Crossref
Katharina Marth, Elisabeth Schuller & Wolfgang Pohl. (2015) Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respiratory Medicine 109:5, pages 616-624.
Crossref
Crossref
K. Suresh Babu & Jaymin B. Morjaria. (2015) Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 9:2, pages 56-68.
Crossref
Crossref
Mario Cazzola, Kai M. Beeh, David Price & Nicolas Roche. (2015) Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. Pulmonary Pharmacology & Therapeutics 31, pages 68-78.
Crossref
Crossref
Leire Braceras & Isabel Elizondo. (2014) Análisis de minimización de costes y del impacto sobre el presupuesto de la Comunidad Autónoma del País Vasco del tratamiento de la enfermedad pulmonar obstructiva crónica moderada a grave con bromuro de aclidinio en lugar de bromuro de tiotropio. PharmacoEconomics Spanish Research Articles 12:2, pages 39-45.
Crossref
Crossref
Domenico Spina. (2015) Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?. European Clinical Respiratory Journal 2:1, pages 26634.
Crossref
Crossref
Jayan George, Shehnoor Tarique & Gwyneth A. Davies. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
195
203
.
Nancy K Leidy, Lindsey T Murray, Brigitta U Monz, Linda Nelsen, Mitchell Goldman, Paul W Jones, Elizabeth J Dansie & Sanjay Sethi. (2014) Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respiratory Research 15:1.
Crossref
Crossref
Gregory J Feldman, Jonathan A Bernstein, Alan Hamilton, Michael C Nivens, Lawrence Korducki & Craig LaForce. (2014) The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies. SpringerPlus 3:1.
Crossref
Crossref
Kai M Beeh, Henrik Watz, Luis Puente-Maestu, Luis de Teresa, Diana Jarreta, Cynthia Caracta, Esther Garcia Gil & Helgo Magnussen. (2014) Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulmonary Medicine 14:1.
Crossref
Crossref
Paolo Montuschi, Mario Malerba, Giuseppe Santini & Marc Miravitlles. (2014) Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discovery Today 19:12, pages 1928-1935.
Crossref
Crossref
Han Ni, Zay Soe & Soe Moe. (2014) Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015:4.
Crossref
Crossref
Etzel Gysling. (2014) Aclidinium. pharma-kritik 36:5.
Crossref
Crossref
Job van der Palen. (2014)
Genuair
®
in chronic obstructive pulmonary disease: a novel, user-friendly, multidose, dry-powder inhaler
. Therapeutic Delivery 5:7, pages 795-806.
Crossref
Crossref
Anthony D D'Urzo, M Reza Maleki-Yazdi & R Andrew McIvor. (2014) Evolving therapies in chronic obstructive pulmonary disease. Clinical Practice 11:3, pages 307-325.
Crossref
Crossref
A. Kirsten & H. Watz. (2014) LABA, LAMA und KombinationenLABA, LAMA and combinations. Der Pneumologe 11:2, pages 127-134.
Crossref
Crossref
Domenico Spina. (2014) Current and novel bronchodilators in respiratory disease. Current Opinion in Pulmonary Medicine 20:1, pages 73-86.
Crossref
Crossref
Nicolas Roche, Niels H Chavannes & Marc Miravitlles. (2013) COPD symptoms in the morning: impact, evaluation and management. Respiratory Research 14:1, pages 112.
Crossref
Crossref